The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

被引：0
作者：
Wen-Chien Cheng
Chi-Chien Lin
Wei-Chih Liao
Yu-Chao Lin
Chia-Hung Chen
Hung-Jen Chen
Chih-Yen Tu
Te-Chun Hsia
机构：
[1] China Medical University Hospital,Division of Pulmonary and Critical Care, Department of Internal Medicine
[2] China Medical University,School of Medicine, College of Medicine
[3] National Chung Hsing University,Department of Life Science
[4] National Chung Hsing University,PhD Program in Translational Medicine
[5] National Chung Hsing University,Rong Hsing Research Center for Translational Medicine
[6] National Chung-Hsing University,Institute of Biomedical Science, the iEGG and Animal Biotechnology Center, Advanced Plant and Food Crop Biotechnology Center
[7] Kaohsiung Medical University,Department of Pharmacology, College of Medicine
[8] Taichung Veterans General Hospital,Department of Medical Research
来源：
BMC Cancer | / 24卷
关键词：
Non-small cell lung cancer (NSCLC); Epidermal growth factor receptor (EGFR); Dacomitinib; Afatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 346 条
  • [1] Deshpand R(2022)Evolving trends in lung cancer: epidemiology, diagnosis, and management Indian J Cancer. 59 S90-S105
  • [2] Chandra M(2014)Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA. 311 1998-2006
  • [3] Rauthan A(2015)A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives Oncotarget. 6 26814-26825
  • [4] Kris MG(2019)Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology Drug Saf. 42 181-198
  • [5] Johnson BE(2019)Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer Br J Cancer. 121 725-737
  • [6] Berry LD(2019)A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients Indian J Med Res. 150 67-72
  • [7] Kwiatkowski DJ(2017)A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations Br J Cancer. 116 568-574
  • [8] Iafrate AJ(2016)Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L J Clin Oncol. 34 3248-3257
  • [9] Wistuba II(2016)Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-lung 7 study Ann Transl Med. 4 476-1466
  • [10] Varella-Garcia M(2017)Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Lancet Oncol. 18 1454-36
12345678910